Michael Goodman, M.D., F.A.C.P., Curriculum Vitae - Glacier Oncology

SELECTED PRESENTATIONS1. World Health Organization: Geneva, Switzerland, 1990. Immune-enhancing activities of 7,8-disubstituted guanine ribonucleoside structural analogues: relevance to vaccines forcommunicable diseases.2. Sandoz Pharmaceuticals Ltd: Basel, Switzerland, 1995. Application of selectively B-cellimmuno-suppressive substituted guanine nucleoside analogues to treatment of chronic graftversus-hostdisease.3. Johnson & Johnson Biosciences Advisory Committee: La Jolla, CA., 1992. Clinicalapplications and mechanism of action of Loxoribine.4. Johnson & Johnson Biosciences Advisory Committee: La Jolla, CA., 1991.Immimobiological activity of the class of substituted guanine ribonucleosides.5. Ortho Pharmaceutical Corp.: Raritan, NJ., 1990. Recent developments in the synthesis andactivity of substituted guanine ribonucleosides.6. Federation of the American Societies for Experimental Biology: New Orleans, LA, 1990. C-Kinase independent restoration of specific immune responsiveness in common variableimmunodeficiency.7. La Jolla Pharmaceuticals: La Jolla, CA. 1991. Substituted guanine nucleosides andautoimmunity.8. Ortho Pharmaceutical Corp.: Toronto, Ontario. 1991. New synthetic structures and backbonesfor oligomeric polynucleotides containing substituted guanine bases: effects onimmunoenhancing activity.9. AIDS research and human retroviruses: Washington, D.C., 1993. Loxoribine: a disubstitutedguanosine with adjuvant activity.10. The Scripps Clinic, Department of Allergy and Immunology: La Jolla, CA., 1994.Immunobiological activities of Loxoribine.11. Federation of the American Societies for Experimental Biology: Anaheim, CA, 1994.Induction of CLL B cell activation and sensitivity to cycle-active cytotoxic agents.12. The Scripps Research Institute, Department of Immunology Retreat: Rancho Valencia, CA.1994. B lymphocyte signaling and stimulation.13. John Wayne Cancer Institute, Santa Monica, CA, 1995: Heightened efficacy of cancer vaccinesin combination with 7,8-disubstituted guanine ribonucleoside structural analogues.14. 9th International Congress of Immunology: San Francisco, CA., 1995. Role of cytokines inNK cell and proliferative responses to Loxoribine.15. Federation of the American Societies for Experimental Biology: Boston, MA, 1995.Intracellular nucleoside-binding proteins with specificity for loxoribine.16. The Scripps Research Institute, La Jolla, CA. 1995: Hematology/Oncology Fellows lecture.17. Genzyme Corp: Boston, MA, 1995. Immunological activities of 7,8-disubstituted guanineribonucleoside structural analogues.18. St. John's Lutheran Hospital, Libby, MT. 1997. Significance of serologic tumor markers inbreast cancer.19. Kalispell Regional Medical Center, Kalispell, MT. 1998. Nursing CME lecture: Update on20